Eiger Biopharmaceuticals Inc Quick Ratio (EIGR) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Eiger Biopharmaceuticals Inc   (NASDAQ: EIGR)

Eiger Biopharmaceuticals Inc 's Quick Ratio

EIGR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2023, Quick Ratio fell to 0.48 a new company low.

Within Biotechnology & Pharmaceuticals industry 142 other companies have achieved higher Quick Ratio than Eiger Biopharmaceuticals Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 1300 to 2505.

Explain Quick Ratio?
How much Cash & cash equivalents EIGR´s has?
What are EIGR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EIGR Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change 89.18 % -36.85 % -23.44 % -34.58 % -9.93 %
Y / Y Cash & cash equivalent Change -1.39 % 4.53 % -37.16 % -67.4 % -75.68 %
Quick Ratio MRQ 0.48 1.69 1.4 0.64 0.92
EIGR's Total Ranking # 2505 # 1300 # 1503 # 2261 # 1726
Seq. Current Liabilities Change 226 % -0.45 % -30.44 % -16.21 % 8.82 %
Seq. Cash & cash equivalent Change -7.49 % 19.66 % 51.39 % -41.15 % -1.94 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 143
Healthcare Sector # 765
Overall Market # 2505


Quick Ratio Statistics
High Average Low
32.86 8.28 0.48
(Mar 31 2014)   (Dec 31 2023)




Financial Statements
Eiger Biopharmaceuticals Inc 's Current Liabilities $ 53 Millions Visit EIGR's Balance sheet
Eiger Biopharmaceuticals Inc 's Cash & cash equivalent $ 25 Millions Visit EIGR's Balance sheet
Source of EIGR's Sales Visit EIGR's Sales by Geography


Cumulative Eiger Biopharmaceuticals Inc 's Quick Ratio

EIGR's Quick Ratio for the trailling 12 Months

EIGR Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -1.73 % -26.29 % -14.66 % -4.81 % 31.32 %
Y / Y Cash & cash equivalent TTM Growth -32.63 % -57.56 % -62.15 % -61.09 % -64.49 %
Quick Ratio TTM 0.83 1.08 0.96 1.05 1.21
Total Ranking TTM # 4074 # 1002 # 3127 # 3917 # 3304
Seq. Current Liabilities TTM Growth 29.71 % -10.14 % -5.07 % -11.18 % -2.71 %
Seq. Cash & cash equivalent TTM Growth -0.39 % 1.32 % -13.08 % -23.2 % -37.25 %

Quick ratio ranking by company, industry and sector >> Back to EIGR Financial Strength Comparisons >> Go to Compare EIGR Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2023 to $53.20 millions, cumulative Quick Ratio decreased to 0.83 below the Eiger Biopharmaceuticals Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 159 other companies have achieved higher Quick Ratio than Eiger Biopharmaceuticals Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 1002 to 4074.

Explain Quick Ratio?
How much Cash & cash equivalents EIGR´s has?
What are EIGR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 160
Healthcare Sector # 1002
Within the Market # 4074


trailing twelve months Quick Ratio Statistics
High Average Low
12.02 5.93 0.82
(Mar 31 2017)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Alpha Cognition Inc.  1.29 $ 2.808  Millions$ 2.185  Millions
Windtree Therapeutics Inc  1.21 $ 4.319  Millions$ 3.560  Millions
Bluebird Bio Inc   1.11 $ 221.755  Millions$ 200.113  Millions
Adma Biologics Inc   1.06 $ 51.352  Millions$ 48.579  Millions
Cyclo Therapeutics Inc   1.00 $ 9.247  Millions$ 9.235  Millions
Pluri Inc   0.95 $ 5.360  Millions$ 5.621  Millions
Ladrx Corporation  0.94 $ 2.070  Millions$ 2.201  Millions
Halozyme Therapeutics Inc   0.88 $ 118.370  Millions$ 134.412  Millions
Tracon Pharmaceuticals Inc   0.84 $ 8.564  Millions$ 10.182  Millions
Valneva Se  0.79 $ 141.210  Millions$ 177.927  Millions
Protalix Biotherapeutics inc   0.76 $ 23.634  Millions$ 31.105  Millions
Evaxion A  0.75 $ 6.398  Millions$ 8.489  Millions
Sangamo Therapeutics Inc   0.68 $ 45.204  Millions$ 66.051  Millions
Elutia Inc   0.62 $ 19.276  Millions$ 31.296  Millions
Qiagen N v   0.59 $ 487.060  Millions$ 821.401  Millions
Cidara Therapeutics Inc   0.53 $ 35.778  Millions$ 67.418  Millions
Kiromic Biopharma Inc   0.50 $ 3.204  Millions$ 6.378  Millions
Outlook Therapeutics Inc   0.50 $ 23.392  Millions$ 46.732  Millions
Amgen Inc   0.49 $ 10,944.000  Millions$ 22,404.000  Millions
Eiger Biopharmaceuticals Inc   0.48 $ 25.440  Millions$ 53.200  Millions
Champions Oncology Inc   0.47 $ 10.118  Millions$ 21.733  Millions
Scinai Immunotherapeutics Ltd  0.46 $ 1.420  Millions$ 3.074  Millions
Zeo Scientifix Inc   0.44 $ 1.764  Millions$ 4.010  Millions
Coherus Oncology inc   0.38 $ 117.748  Millions$ 310.250  Millions
Atara Biotherapeutics Inc   0.36 $ 51.725  Millions$ 142.226  Millions
Vaxart Inc   0.36 $ 4.958  Millions$ 13.724  Millions
Novavax inc   0.35 $ 568.505  Millions$ 1,635.138  Millions
Biocardia Inc   0.31 $ 1.103  Millions$ 3.608  Millions
Agenus Inc  0.30 $ 76.110  Millions$ 255.897  Millions
Mink Therapeutics Inc   0.30 $ 3.367  Millions$ 11.403  Millions

Date modified: 2026-09-18T14:07:35+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.